4 sources·Health

Biden Administration Proposes Expanding Obesity Drug Coverage Under Medicare and Medicaid

The Biden administration's new proposal aims to significantly increase Medicare and Medicaid coverage for anti-obesity medications, addressing the high rates of obesity in America.

The distribution of story sources: left-leaning (blue), center (light gray), and right-leaning (red).
Mostly Reliable
The underlying sources are generally reliable but sometimes include opinion, propaganda, or minor inaccuracies.
Balanced
The underlying sources are either a balanced mix of left and right or primarily centrist.
Subscribe to unlock this story

We really don't like cutting you off, but you've reached your monthly limit. At just $3/month or $30/year, subscriptions are how we keep this project going. Start your free 7-day trial today!

Get Started

No highlights available for this story.

Updated: Nov 27th, 2024, 10:32 AM ET

Summary

A summary of the key points of this story verified across multiple sources.

In a bid to tackle the obesity epidemic affecting 42% of Americans, the Biden administration has proposed expanding Medicare and Medicaid coverage for anti-obesity medications. This would potentially benefit an estimated 3.4 million Medicare and 4 million Medicaid enrollees. The initiative comes as part of a broader agenda to lower healthcare costs. The proposal's fate remains uncertain under the incoming Trump administration, particularly with potential opposition from his appointed health officials. Advocates believe the expansion could save costs in the long term, while critics question its implications for drug pricing.

Perspectives

Compare opinions on this story from liberal (Left), conservative (Right) or center-leaning news organizations.

No center-leaning sources available for this story.